A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.

• Type of Material: Article
• Authors: Daniel Goldstein, Emory University; Jonathon Clark, Davidoff Cancer Center; Yifan Tu, Saint Louis University Hospital; Jie Zhang, First Affiliated Hospital of Dalian Medical University; Fengi Fang, First Affiliated Hospital of Dalian Medical University; Robert Goldstein, University College of London; Salomon M. Stemmer, Davidoff Cancer Center; Eli Rosenbaum, Davidoff Cancer Center
• Language: English
• Date: 2017-09-22
• Publisher: American Heart Association
• Publication Version: Final Published Version
• Copyright Statement: © 2012 American Heart Association, Inc.
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.18632/oncotarget.17742
• Title of Journal or Parent Work: Oncotarget
• Volume: 8
• Issue: 42
• Start Page: 71548
• End Page: 71555
• Grant/Funding Information: FUNDING: None.
• Keywords: cost; affordability
• Research Categories: Health Sciences, Public Health

Abstract

INTRODUCTION: There are major differences in cancer drug prices around the world. However, the patterns of affordability of these drugs are poorly understood. The objective of this study was to compare patterns of affordability of cancer drugs in Australia, China, India, Israel, South Africa, the United Kingdom, and the United States. RESULTS: Cancer drug prices are highest in the United States. Cancer drugs are the least affordable in India by a large margin. Despite lower prices than in the USA, cancer drugs are less affordable in middle-income countries than in high-income countries. MATERIALS AND METHODS: We obtained the prices of a basket of cancer drugs in all 7 countries, and converted the prices to US$ using both foreign exchange rates and purchasing power parity. We assessed international differences in wealth by collecting values for gross domestic product (GDP) per capita in addition to average salaries. We compared patterns of affordability of cancer drugs by dividing the drug prices by the markers of wealth. CONCLUSIONS: Cancer drugs are less affordable in middle-income countries than in high-income countries. Differential pricing may be an acceptable policy to ensure global affordability and access to highly active anti-cancer therapies.